Your browser is no longer supported. Please, upgrade your browser.
ARAV Aravive, Inc. daily Stock Chart
Aravive, Inc.
Index- P/E- EPS (ttm)-1.93 Insider Own0.50% Shs Outstand15.90M Perf Week2.38%
Market Cap89.18M Forward P/E- EPS next Y-1.71 Insider Trans0.00% Shs Float10.96M Perf Month-46.78%
Income-26.30M PEG- EPS next Q-0.40 Inst Own44.70% Short Float9.32% Perf Quarter-48.64%
Sales0.00M P/S- EPS this Y85.20% Inst Trans1.94% Short Ratio4.90 Perf Half Y-38.15%
Book/sh3.74 P/B1.61 EPS next Y8.60% ROA-36.60% Target Price- Perf Year-8.64%
Cash/sh4.06 P/C1.48 EPS next 5Y- ROE-44.80% 52W Range3.34 - 15.62 Perf YTD-55.89%
Dividend- P/FCF- EPS past 5Y43.10% ROI- 52W High-61.40% Beta3.15
Dividend %- Quick Ratio13.50 Sales past 5Y- Gross Margin- 52W Low80.54% ATR0.72
Employees17 Current Ratio13.50 Sales Q/Q- Oper. Margin- RSI (14)26.37 Volatility9.31% 9.35%
OptionableYes Debt/Eq0.00 EPS Q/Q-17.50% Profit Margin- Rel Volume2.25 Prev Close5.57
ShortableYes LT Debt/Eq0.00 EarningsAug 03 AMC Payout- Avg Volume208.75K Price6.03
Recom1.70 SMA20-28.39% SMA50-45.58% SMA200-39.88% Volume469,005 Change8.26%
Dec-10-19Initiated Cantor Fitzgerald Overweight
Dec-02-19Upgrade Robert W. Baird Neutral → Outperform
May-13-19Initiated Piper Jaffray Overweight $10
Apr-09-19Initiated Wedbush Outperform $14
Aug-03-20 04:01PM  
Jul-30-20 07:00AM  
Jul-23-20 07:00AM  
Jul-03-20 01:11PM  
Jul-01-20 08:12AM  
Jun-30-20 04:05PM  
Jun-24-20 05:45PM  
Jun-17-20 05:50PM  
Jun-12-20 12:04PM  
May-12-20 08:00AM  
May-06-20 04:05PM  
May-05-20 05:45PM  
Apr-30-20 08:00AM  
Apr-27-20 05:45PM  
Apr-22-20 07:10AM  
Apr-20-20 09:06AM  
Apr-16-20 10:40AM  
Apr-15-20 08:45AM  
Apr-09-20 07:08AM  
Mar-30-20 08:00AM  
Mar-27-20 08:00AM  
Mar-24-20 08:00AM  
Feb-25-20 04:07PM  
Feb-18-20 08:00AM  
Jan-13-20 08:00AM  
Jan-10-20 07:13AM  
Jan-09-20 04:05PM  
Jan-02-20 08:34AM  
Dec-23-19 07:57PM  
Dec-20-19 08:00AM  
Dec-02-19 08:00AM  
Nov-29-19 08:51AM  
Nov-27-19 08:30AM  
Nov-26-19 05:14PM  
Nov-20-19 04:26PM  
Nov-12-19 08:00AM  
Nov-08-19 01:11PM  
Nov-07-19 04:05PM  
Nov-03-19 07:41AM  
Oct-18-19 08:00AM  
Sep-27-19 10:15AM  
Sep-19-19 08:13AM  
Sep-18-19 08:00AM  
Aug-08-19 04:15PM  
Aug-07-19 08:55PM  
Jul-31-19 03:16PM  
Jul-08-19 07:05AM  
May-08-19 06:35PM  
Apr-25-19 02:26PM  
Mar-19-19 07:05AM  
Mar-15-19 07:48AM  
Mar-11-19 02:14PM  
Mar-08-19 04:05PM  
Mar-07-19 04:04PM  
Mar-05-19 04:05PM  
Feb-28-19 04:10PM  
Feb-19-19 07:00AM  
Feb-14-19 07:00AM  
Jan-29-19 07:00AM  
Dec-11-18 08:05AM  
Nov-26-18 07:00AM  
Nov-13-18 07:00AM  
Nov-06-18 06:38PM  
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, triple negative breast cancer, acute myeloid leukemia, and pancreatic cancer. The company has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.